Physician profile
James M Osher
NPI 1942448618
$11,031.40
in general payments reported to CMS, 2019-2025
21 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $577 · 2020: $338 · 2021: $468 · 2022: $5,072 · 2023: $2,747 · 2024: $808 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,737 · Consulting Fee: $840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,736.66 |
| Consulting Fee | $840.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $5,887.11 | 2019-2025 | Vabysmo, Susvimo, Lucentis |
| Regeneron Healthcare Solutions, INC. | $2,305.03 | 2019-2025 | Eylea Hd, Eylea |
| Alimera Sciences, INC. | $573.76 | 2020-2024 | Iluvien, Yutiq |
| Astellas Pharma US INC | $344.04 | 2023-2025 | Izervay |
| Allergan, INC. | $332.00 | 2019-2021 | |
| Alcon Vision LLC | $305.36 | 2019-2025 | Centurion, Rocklatan, Ngenuity |
| Apellis Pharmaceuticals, INC. | $254.18 | 2022-2025 | Syfovre |
| Eyepoint US, INC. | $200.77 | 2020-2021 | |
| Abbvie INC. | $184.76 | 2022-2025 | |
| Genentech, INC. | $154.33 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $87.56 | 2021 | |
| Bausch & Lomb Americas INC. | $85.72 | 2022-2025 | Xiidra, Vyzulta |
| Regeneron Pharmaceuticals, INC. | $73.94 | 2024 | Eylea, Eylea Hd |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Ani Pharmaceuticals, INC. | $58.79 | 2025 | Iluvien, Yutiq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $48.92 | 2019-2020 | |
| Biotissue Holdings INC. | $30.71 | 2023 | |
| Dutch Ophthalmic, USA | $20.32 | 2025 | Eva, Combined Machine, Tissueblue |
| Harrow Eye, LLC | $19.39 | 2025 | Vevye |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Osher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.